文献速递炎症性肠病

Darvadstrocel治疗克罗恩病复杂肛瘘:ADMIRE CD II III期随机试验

Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.
PubMed 文献 · Gastroenterology · 2026-03-06

ADMIRE CD II是一项在歐洲、以色列和北美开展的III期双盲随机安慰剂对照试验,纳入568例对免疫抑制剂或生物制剂应答不足的克罗恩病复杂肛瘘成人患者。两组治疗中出现的不良事件发生率相似,未发现新的安全性信号。

要点

  • darvadstrocel第24周联合缓解率48.8% vs 安慰剂46.3%,差异无统计学意义。
  • 关键次要终点(第24周临床缓解及至临床缓解时间)也无显著差异。
  • 治疗中出现的不良事件发生率两组相似(73.0% vs 73.4%),无新安全性信号。

核心结论

  • ADMIRE CD II未达到第24周联合缓解的主要终点,darvadstrocel与安慰剂之间无统计学显著差异。
  • 未发现darvadstrocel新的安全性信号。

研究设计与样本

  • III期、双盲、随机、安慰剂对照试验(ADMIRE CD II,NCT03279081),在歐洲、以色列和北美开展。
  • 纳入成人克罗恩病合并复杂肛瘘、内口≤2个且外口≤3个、对免疫抑制剂或生物制剂应答不足的患者。
  • 按1:1随机接受darvadstrocel(120×10^6个干细胞分散于24 mL无菌缓冲液)或安慰剂,两组均行瘘管刮除和内口闭合。
  • 共随机568例(darvadstrocel组283例,安慰剂组285例),分别有249例和246例完成试验。

主要发现

  • 第24周联合缓解(所有治疗外口闭合且无>2 cm的集合)在darvadstrocel组为138/283(48.8%),安慰剂组为132/285(46.3%)。
  • 治疗中出现的不良事件在darvadstrocel组为203/278(73.0%),安慰剂组为201/274(73.4%)。

临床怎么用

  • 在更广泛的患者人群中,darvadstrocel未显示出优于安慰剂的联合缓解率,不支持其在该人群中的常规使用。
  • 治疗相关不良事件发生率与安慰剂相似,安全性特征未发现新信号。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The ADMIRE CD trial demonstrated the efficacy and safety of darvadstrocel in patients with complex perianal fistulas from Europe and Israel. The efficacy and safety of darvadstrocel in an expanded patient population was investigated. METHODS: ADMIRE CD II (ClinicalTrials.gov, Number: NCT03279081) was a phase 3, double-blind, randomized, placebo-controlled trial conducted in Europe, Israel, and North America. Adults with Crohn's disease and complex perianal fistulas with ≤2 internal openings and ≤3 external openings and inadequate response to immunosuppressive agents or biologics were randomized 1:1 to receive darvadstrocel (a dispersion of 120 × 106 stem cells in 24 mL sterile buffered solution) or placebo. Both groups underwent curettage and closure of the internal opening. The primary endpoint was combined remission (closure of all treated external openings and absence of collections >2 cm) at week 24. RESULTS: Overall, 568 patients were randomized to receive darvadstrocel (n = 283) or placebo (n = 285); 249 and 246, respectively, completed the trial. At week 24, combined remission was achieved in 138 of 283 (48.8%) patients in the darvadstrocel group and 132 of 285 (46.3%) in the placebo group (estimated treatment difference: 2.4%; 95% CI, -5.8 to 10.6; P = .571). There were no significant differences in key secondary endpoints for darvadstrocel vs placebo (clinical remission at week 24 [P = .515] and time to clinical remission [P = .374]). Treatment-emergent adverse events were infrequent and experienced by similar proportions of patients receiving darvadstrocel (203/278 [73.0%]) and placebo (201/274 [73.4%]). CONCLUSIONS: ADMIRE CD II did not meet its primary endpoint of combined remission at week 24, with no statistically significant difference between darvadstrocel and placebo. No new safety signals were identified for darvadstrocel. CLINICALTRIALS: gov, Number: NCT002209456.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Colombel JF, Garcia Olmo D, Chen ST, et al. Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial. Gastroenterology. 2026. PMID: 41790076. doi:10.1053/j.gastro.2025.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。